Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate effects on neurometabolites in boys with ADHD
IRCT20201105049271N1Phase 3Completed
- Sponsor
- Institute for Cognitive Science Studies
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Institute for Cognitive Science Studies. Primary endpoints: Prefronto-cerebellar neurometabolites, CANTAB variables and 3 more. Started Jul 2019; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20201105049271N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201105049271N1.